Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setting on cancer care and quality of life. Currently, most drug-related cancer care is conducted in clinic type centers or hospitals which may isolate patients from family, friends and familiar surroundings for many hours per day. This separation adds to the physical, emotional, social, and financial burden for patients and their families. Traveling to and from medical facilities costs time, money, and effort and can be a disadvantage to patients living in rural areas, those with

Trial Details

NCT ID

NCT06265285

Phase

PHASE2

Sponsor

Mayo Clinic

Status

RECRUITING

Cancer Type

Adenocarcinoma Lung Cancer

Interventions

Home Health Encounter
Nivolumab
Patient Monitoring
Questionnaire Administration

Locations (sample)

Jacksonville, Florida, United States|30.33218,-81.65565

Key Eligibility Criteria

Age ≥ 18 years
Histologically confirmed malignancies for which treatment with intravenous nivolumab is currently Food and Drug Administration (FDA) approved and w…
Single agent nivolumab administered in the adjuvant setting for one of the following indications:
Completely resected stage IIB/C, III or IV melanoma

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →